June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Peripheral lymphocytes as a source of biomarkers in POAG
Author Affiliations & Notes
  • Stefano Gandolfi
    Ophthalmology, University of Parma, Parma, Italy
  • Nicola Ungaro
    Ophthalmology, University of Parma, Parma, Italy
  • Luigi Varano
    Ophthalmology, University of Parma, Parma, Italy
  • raffaella aldigeri
    Ophthalmology, University of Parma, Parma, Italy
  • piergiorgio petronini
    Medicine, Univ. of Parma, Pathology, Parma, Italy
  • silvia lamonica
    Medicine, Univ. of Parma, Pathology, Parma, Italy
  • Footnotes
    Commercial Relationships   Stefano Gandolfi, None; Nicola Ungaro, None; Luigi Varano, None; raffaella aldigeri, None; piergiorgio petronini, None; silvia lamonica, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3747. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stefano Gandolfi, Nicola Ungaro, Luigi Varano, raffaella aldigeri, piergiorgio petronini, silvia lamonica; Peripheral lymphocytes as a source of biomarkers in POAG. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3747.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : to measure (a) the apoptotic response to oxidative stress in lymphocytes of OAG, OH and controls, (b) the prevalence of T-reg (Cd4-Cd25) lymphocytes in OAG and controls and (c) correlate them with the 10-yr rate of field progression

Methods : consecutive patients referring to the Glaucoma Clinic were screened. 56 patients with POAG, 56 matched controls and 41 ocular hypertensives were enrolled in the "apoptotic response study". 18 patients with POAG and 18 matched controls were enrolled in the "autoimmunity" study. Blood samples were processed as follows: (a) "apoptotic response": 2-hrs incubation of Lymphocytes, upon amplification with PHA, with increasing concentrations of H2O2 (up to 100 mM) , 16-hr recovery, apoptosis evaluated by DNA fragmentation test and Annexin V test;(b)"autoimmunity ":Flow cytometriy to determine the CD4+CD25+FOXP3 lympho population. After magnetic cell separation of CD4+CD25-(Tresp) and Treg cells, the suppression function of Tregs was assessed using the in vitro suppression test (Treg suppression Inspector, Miltenyi Biotec).
POAG and OH were followed up to 10 years.The following data were collected every 6 months:(a)visual field (SAP 24/2 SITA st),(b)optic disc (HRT2-3),(c)IOP and CCT,(d)visual acuity,(e)blood pressure,(f) medications and concomitant systemic therapies.Main outcome:rate of progression of visual field (RoP).Secondary outcome(s):(a) progression of optic disc,(b) changes of therapy,(c) conversion from OH to POAG.RoP was calculated by trend analyses of (a) the MD and (b) the glaucoma hemifield clusters.

Results : Both the basal apoptotic index and the response to peroxide were higher in POAG vs controls and OH, whose values were superimposable. The % reponse to peroxide correlated significantly with 10-yr VF RoP (r2 = 0.746) .After a multivariate analysis, the following factors were significantly associated with faster RoP: % respose to peroxide, > 2 changes of therapy and age.CCT was protective.
The median value of Tregs (%) in POAG patients was 5.55 vs. 4.28 in controls (p=0.005).No significant difference in the suppression activity of Tregs was observed between POAG controls (88 and 94% of suppression in the 1:1 co-colture, p=0.118).MD RoP was 0,794+0,71 dB /year in glaucoma patients.The RoP correlated with the % T-regs in the individual patients (r = 0.774, p < 0.001).RoP proved surprisingly unrelated to the mean IOP.

Conclusions : peripheral lymphocytes can provide biomarkers for POAG

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×